All In Biotech

Drug Trial Radar · NCT06071624

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

CD4CAR T Cell Therapy for CMML

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 21, 2024

Primary completion

Dec 2028

Study completion Dec 2043

Sponsor

Lead sponsor
Huda SalmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
iCell Gene Therapeutics; The Leukemia and Lymphoma Society
First posted
Oct 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.

Conditions

  • Chronic Myelomonocytic Leukemia

Interventions

  • CD4CARBiological

    CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose finding: Maximum tolerated dose (MTD) is defined as one dose level lower than the dose limiting toxicity (DLT) of the CD4CAR in CMMLTime frame: Day 0 through Day 28 post-infusion
  2. The efficacy of treatment with CD4CAR and description of CMML response to CD4CARTime frame: Day 28 through 6 months post-infusion

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136

    Miami, Florida

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • Albert Einstein Health Network

    The Bronx, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.